NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.809
+0.058 (7.78%)
At close: Apr 28, 2026, 4:00 PM EDT
0.791
-0.018 (-2.23%)
After-hours: Apr 28, 2026, 6:19 PM EDT
NeuroSense Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for NeuroSense Therapeutics stock have an average target of 8.50, with a low estimate of 3.00 and a high estimate of 14. The average target predicts an increase of 950.81% from the current stock price of 0.81.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NeuroSense Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 1 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Apr 8, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Mar 25, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Mar 17, 2026 |
| Roth Capital | Roth Capital | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +270.87% | Mar 10, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Mar 9, 2026 |
Financial Forecast
Revenue This Year
728.28K
Revenue Next Year
4.98M
from 728.28K
Increased by 583.67%
EPS This Year
-0.32
from -0.44
EPS Next Year
-0.43
from -0.32
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.2M | 8.5M | ||||||
| Avg | 728,280 | 5.0M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 1,065.9% | ||||||
| Avg | - | 583.7% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.19 | -0.20 | ||||||
| Avg | -0.32 | -0.43 | ||||||
| Low | -0.39 | -0.80 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.